<p>Unicycive Therapeutics, Inc. (NASDAQ:UNCY - 获取免费报告) 的股价在周五上涨了 1%。该股票最高交易价为 6.35 美元，最后交易价为 6.18 美元。在午盘交易中，约有 388,927 股成交，较 328,233 股的日均成交量增加了 18%。该股票此前收盘价为 6.12 美元。</p>
<p>获取 <strong>Unicycive Therapeutics</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>几位股票研究分析师对 UNCY 股票发表了评论。HC Wainwright 在 10 月 29 日的研究报告中重申了 “买入” 评级，并将 Unicycive Therapeutics 的目标价上调至 22.00 美元（从 9.00 美元上调）。Benchmark 在 9 月 15 日的研究报告中将 Unicycive Therapeutics 的目标价提升至 21.00 美元，并给予该股票 “投机性买入” 评级。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了 Unicycive Therapeutics 的 “卖出（d-）” 评级。华尔街 Zen 在 11 月 2 日的报告中将 Unicycive Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，Guggenheim 在 12 月 30 日的研究报告中重申了 Unicycive Therapeutics 的 “买入” 评级。三位研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 34.33 美元。</p>
<p><strong>获取我们关于 UNCY 的最新研究报告</strong></p>
<h2>Unicycive Therapeutics 的价格表现</h2>
<p>该公司的 50 日简单移动平均线为 5.71 美元，200 日简单移动平均线为 4.95 美元。该公司的市值为 1.3281 亿美元，市盈率为-1.56，贝塔值为 1.85。</p>
<p>Unicycive Therapeutics (NASDAQ:UNCY - 获取免费报告) 最近于 11 月 12 日发布了季度财报。该公司报告每股收益（EPS）为-0.39 美元，超出分析师一致预期的-0.59 美元，超出幅度为 0.20 美元。股票研究分析师预测 Unicycive Therapeutics, Inc.在当前财政年度将发布每股收益-0.23 美元。</p>
<h2>Unicycive Therapeutics 的机构交易</h2>
<p>几家对冲基金和其他机构投资者最近调整了对该公司的持股。Lazard Asset Management LLC 在第二季度以 55,000 美元的估值收购了 Unicycive Therapeutics 的新头寸。摩根大通在第二季度将其在 Unicycive Therapeutics 的持股增加了 11,698.4%。摩根大通现在拥有 21,709 股该公司的股票，估值为 104,000 美元，此前在上一季度增持了 21,525 股。Citadel Advisors LLC 在第三季度以约 182,000 美元的估值收购了 Unicycive Therapeutics 的新头寸。Squarepoint Ops LLC 在第三季度以约 512,000 美元的估值收购了 Unicycive Therapeutics 的新头寸。最后，先锋集团在第三季度将其在 Unicycive Therapeutics 的持股增加了 8.7%。先锋集团现在拥有 658,878 股该公司的股票，价值 2,873,000 美元，此前在上一季度增持了 52,925 股。机构投资者和对冲基金持有该公司 40.42% 的股份。</p>
<h2>关于 Unicycive Therapeutics</h2>
<p>(获取免费报告)</p>
<p>Unicycive Therapeutics, Inc.是一家生物技术公司，专注于在美国开发治疗肾脏疾病的新疗法。该公司正在开发 Renazorb 用于治疗慢性肾病透析患者的高磷血症；以及 UNI 494，目前正在进行 1 期临床试验以治疗急性肾损伤。该公司成立于 2016 年，总部位于加利福尼亚州洛斯阿尔托斯。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Unicycive Therapeutics 更好</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
<li>今年你花的最值得的 19 美元。</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Unicycive Therapeutics 吗？</h2>
<p>在你考虑 Unicycive Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Unicycive Therapeutics 并不在名单上。</p>
<p>虽然 Unicycive Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>查看这五只股票</p>

UNCY

<p>Unicycive Therapeutics (NASDAQ:UNCY) 的股价上涨了 1%，达到 6.18 美元，交易量增加了 18%。分析师们设定了新的价格目标，HC Wainwright 将其目标提高至 22.00 美元，Benchmark 则为 21.00 美元，两者均维持买入评级。该公司报告的季度每股收益为-0.39 美元，超出预期。机构投资者持有该股票的 40.42%。Unicycive 专注于开发肾脏疾病的治疗方案。尽管评级为适度买入，但一些分析师建议其他股票可能是更好的投资选择</p>

<p>Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report)'s share price was up 1% on Friday . The stock traded as high as $6.35 and last traded at $6.18. Approximately 388,927 shares traded hands during mid-day trading, an increase of 18% from the average daily volume of 328,233 shares. The stock had previously closed at $6.12.</p>
<div class="lb-trans"><p>Unicycive Therapeutics, Inc. (NASDAQ:UNCY - 获取免费报告) 的股价在周五上涨了 1%。该股票最高交易价为 6.35 美元，最后交易价为 6.18 美元。在午盘交易中，约有 388,927 股成交，较 328,233 股的日均成交量增加了 18%。该股票此前收盘价为 6.12 美元。</p>
</div><p>Get <strong>Unicycive Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Unicycive Therapeutics</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Several equities research analysts have commented on UNCY shares. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $22.00 price target (up from $9.00) on shares of Unicycive Therapeutics in a research report on Wednesday, October 29th. Benchmark lifted their price objective on shares of Unicycive Therapeutics to $21.00 and gave the stock a &#34;speculative buy&#34; rating in a research note on Monday, September 15th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Unicycive Therapeutics in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Unicycive Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, November 2nd. Finally, Guggenheim restated a &#34;buy&#34; rating on shares of Unicycive Therapeutics in a research report on Tuesday, December 30th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $34.33.</p>
<div class="lb-trans"><p>几位股票研究分析师对 UNCY 股票发表了评论。HC Wainwright 在 10 月 29 日的研究报告中重申了 “买入” 评级，并将 Unicycive Therapeutics 的目标价上调至 22.00 美元（从 9.00 美元上调）。Benchmark 在 9 月 15 日的研究报告中将 Unicycive Therapeutics 的目标价提升至 21.00 美元，并给予该股票 “投机性买入” 评级。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了 Unicycive Therapeutics 的 “卖出（d-）” 评级。华尔街 Zen 在 11 月 2 日的报告中将 Unicycive Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，Guggenheim 在 12 月 30 日的研究报告中重申了 Unicycive Therapeutics 的 “买入” 评级。三位研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 34.33 美元。</p>
</div><p><strong>Get Our Latest Research Report on UNCY</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 UNCY 的最新研究报告</strong></p>
</div><h2>Unicycive Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Unicycive Therapeutics 的价格表现</h2>
</div><p>The firm's fifty day simple moving average is $5.71 and its 200 day simple moving average is $4.95. The company has a market capitalization of $132.81 million, a price-to-earnings ratio of -1.56 and a beta of 1.85.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 5.71 美元，200 日简单移动平均线为 4.95 美元。该公司的市值为 1.3281 亿美元，市盈率为-1.56，贝塔值为 1.85。</p>
</div><p>Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.20. Equities research analysts forecast that Unicycive Therapeutics, Inc. will post -0.23 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Unicycive Therapeutics (NASDAQ:UNCY - 获取免费报告) 最近于 11 月 12 日发布了季度财报。该公司报告每股收益（EPS）为-0.39 美元，超出分析师一致预期的-0.59 美元，超出幅度为 0.20 美元。股票研究分析师预测 Unicycive Therapeutics, Inc.在当前财政年度将发布每股收益-0.23 美元。</p>
</div><h2>Institutional Trading of Unicycive Therapeutics</h2>
<div class="lb-trans"><h2>Unicycive Therapeutics 的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the business. Lazard Asset Management LLC acquired a new position in Unicycive Therapeutics during the second quarter valued at $55,000. JPMorgan Chase &amp; Co. grew its stake in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase &amp; Co. now owns 21,709 shares of the company's stock valued at $104,000 after acquiring an additional 21,525 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at about $182,000. Squarepoint Ops LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at about $512,000. Finally, Vanguard Group Inc. lifted its position in shares of Unicycive Therapeutics by 8.7% in the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company's stock worth $2,873,000 after purchasing an additional 52,925 shares in the last quarter. Institutional investors and hedge funds own 40.42% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对该公司的持股。Lazard Asset Management LLC 在第二季度以 55,000 美元的估值收购了 Unicycive Therapeutics 的新头寸。摩根大通在第二季度将其在 Unicycive Therapeutics 的持股增加了 11,698.4%。摩根大通现在拥有 21,709 股该公司的股票，估值为 104,000 美元，此前在上一季度增持了 21,525 股。Citadel Advisors LLC 在第三季度以约 182,000 美元的估值收购了 Unicycive Therapeutics 的新头寸。Squarepoint Ops LLC 在第三季度以约 512,000 美元的估值收购了 Unicycive Therapeutics 的新头寸。最后，先锋集团在第三季度将其在 Unicycive Therapeutics 的持股增加了 8.7%。先锋集团现在拥有 658,878 股该公司的股票，价值 2,873,000 美元，此前在上一季度增持了 52,925 股。机构投资者和对冲基金持有该公司 40.42% 的股份。</p>
</div><h2>About Unicycive Therapeutics</h2>
<div class="lb-trans"><h2>关于 Unicycive Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.</p>
<div class="lb-trans"><p>Unicycive Therapeutics, Inc.是一家生物技术公司，专注于在美国开发治疗肾脏疾病的新疗法。该公司正在开发 Renazorb 用于治疗慢性肾病透析患者的高磷血症；以及 UNI 494，目前正在进行 1 期临床试验以治疗急性肾损伤。该公司成立于 2016 年，总部位于加利福尼亚州洛斯阿尔托斯。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Unicycive Therapeutics</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>First Time Since 2007: All Warnings Active</li>
<li>Best $19 you’ll spend this year.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Unicycive Therapeutics 更好</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
<li>今年你花的最值得的 19 美元。</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Unicycive Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Unicycive Therapeutics 吗？</h2>
</div><p>Before you consider Unicycive Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Unicycive Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Unicycive Therapeutics 并不在名单上。</p>
</div><p>While Unicycive Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Unicycive Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Unicycive Therapeutics（NASDAQ:UNCY）股价上涨 1% - 你应该购买吗？